Dr. He Ruyi, our Chief Medical Officer, is one of the most authoritative experts in China in the areas of clinical development and global regulatory regimes for medical products. He brings us nearly 20 years of experience working at the FDA in the U.S. and the NMPA in China. In the more than 17 years with the FDA, he held a number of strategic leadership positions and chaired several working groups that were tasked with drafting and finalizing guidelines for the pharmaceutical industry. He was also involved in FDA guidance development in multiple therapeutic areas. In China, Dr. He was Chief Scientist at the Center for Drug Evaluation (CDE) of the NMPA where he led multiple important policy initiatives. In addition to his policy-making roles with both the FDA and the NMPA, Dr. He also gained first-hand experience reviewing and approving numerous applications for INDs and NDAs in both the U.S. and China. A prolific author, Dr. He has also published more than 20 research papers and abstracts in the fields of drug regulatory science and internal medicine. Dr. He received his medical degree from China Medical University. He completed his intern and residency training in Internal Medicine at Howard University Hospital in Washington, D.C. He received his clinical research training at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH) in Bethesda, Maryland. Dr. He is a licensed, board-certified physician in internal medicine in the U.S.